The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
CTLA-4: From mechanism to autoimmune therapy
Abstract
CD28 and CTLA-4 are both important stimulatory receptors for the regulation of T cell activation. Because receptors share common ligands, B7.1 and B7.2, the expression and biological function of CTLA-4 is important for the negative regulation of T cell responses. Therefore, elimination of CTLA-4 can result in the breakdown of immune tolerance and the development of several diseases such as autoimmunity. Inhibitory signals of CTLA-4 suppress T cell responses and protect against autoimmune diseases in many ways. In this review, we summarize the structure, expression and signaling pathway of CTLA-4. We also highlight how CTLA-4 defends against potentially self-reactive T cells. Finally, we discuss how the CTLA-4 regulates a number of autoimmune diseases that indicate manipulation of this inhibitory molecule is a promise as a strategy for the immunotherapy of autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–256 of 256
Matsushita, M., Tsuchiya, N., Shiota, M., Komata, T., Matsuta, K., Zama, K., Oka, T., Juji, T., Yamane, A., & Tokunaga, K. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.540607.x · Cited by 60
Alten, R., Kaine, J., Keystone, E. C., Nash, P. T., Delaet, I., & Genovese, M. C. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38687 · Cited by 59
Barton, A. C., Jury, F., Eyre, S., Bowes, J., Hinks, A., Ward, D., & Worthington, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20118 · Cited by 59
Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis
Han, S., Li, Y., Mao, Y., & Xie, Y. (2005) · Human Genetics · doi:10.1007/s00439-005-0033-9 · Cited by 57
Zalloua, P., Abchee, A., Shbaklo, H., Zreik, T. G., Terwedow, H. A., Halaby, G., & Azar, S. T. (2004) · Human Immunology · doi:10.1016/j.humimm.2004.04.007 · Cited by 54
Haller, K., Kisand, K., Pisarev, H., Salur, L., Laisk, T., Nemvalts, V., & Uibo, R. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00745.x · Cited by 54
Keystone, E. C., Kremer, J. M., RUSSELL, A. S., Box, J., Abud‐Mendoza, C., Garza‐Elizondo, M. A., Luo, A. Y., Aranda, R., Delaet, I., Swanink, R., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200355 · Cited by 53
Ivan Balic, N., Bárbara Angel, B., Ethel Codner, D., Carrasco, E., & Pérez‐Bravo, F. (2009) · Human Immunology · doi:10.1016/j.humimm.2008.12.007 · Cited by 49
Abe, T., Takino, H., Yamasaki, H., Ozaki, M., Sera, Y., Kondo, H., Sakamaki, H., Kawasaki, E., Awata, T., Yamaguchi, Y., et al. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00084-4 · Cited by 48
Dyment, D. A., Steckley, J. L., Willer, C. J., Armstrong, H., Sadovnick, A. D., RISCH, N. J., & Ebers, G. C. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00493-3 · Cited by 48
van Veen, T., Crusius, J. B. A., van Winsen, L., Xia, B., Barkhof, F., Peña, A. S., Polman, C. H., & Uitdehaag, B. M. J. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00184-x · Cited by 48
Benmansour, J., Stayoussef, M., Al-Jenaidi, F. A., Rajab, M. H., Rayana, C. B., Said, H. B., Mahjoub, T., & Almawi, W. Y. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00099-10 · Cited by 47
Finckh, A., Neto, D., Iannone, F., Loza, E., Lie, E., van Riel, P. L. C. M., Hetland, M. L., Pavelká, K., Gottenberg, J., Canhão, H. M., et al. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000040 · Cited by 46
Choi, J., Kim, S., Shin, J.-H., Gibson, T. F., Yoon, B.-S., Lee, D., Lee, S.-K., Bothwell, A. L. M., Lim, J.-S., & Lee, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805198105 · Cited by 45
Suppiah, V., Alloza, I., Heggarty, S., Goris, A., Dubois, B., Carton, H., & Vandenbroeck, K. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.003 · Cited by 43
Memory B Cells and Response to Abatacept in Rheumatoid Arthritis
Gazeau, P., Alegria, G. C., Devauchelle‐Pensec, V., Jamin, C., Lemerle, J., Bendaoud, B., Brooks, W. H., Saraux, A., Cornec, D., & Renaudineau, Y. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8603-x · Cited by 43
CTLA‐4 Gene Polymorphism Contributes to the Genetic Risk for Latent Autoimmune Diabetes in Adults
Cosentino, A., Gambelunghe, G., Tortoioli, C., & Falorni, A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb03000.x · Cited by 42
IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression
Gharibi, T., Hosseini, A., Marofi, F., Oraei, M., Jahandideh, S., Abdollahpour‐Alitappeh, M., Hashemi, V., Motallebnezhad, M., Babaloo, Z., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.09.003 · Cited by 40
Self-citationGenovese, M. C., Pacheco‐Tena, C., Covarrubias, A., León, G., Mysler, E., Keiserman, M. W., Valente, R. M., Nash, P. T., Campos, J. A. S., Box, J., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170344 · Cited by 39
Hu, H., Rudd, C. E., & Schneider, H. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5814 · Cited by 38
Cytotoxic T‐lymphocyte antigen‐4‐CT60 polymorphism in rheumatoid arthritis
Orozco, G., Torres, B., Núñez‐Roldán, A., González‐Escribano, M. F., & Martin, J. J. (2004) · Tissue Antigens · doi:10.1111/j.1399-0039.2004.00318.x · Cited by 38
Association of CTLA-4 (+49A/G) Gene Polymorphism with Type 1 Diabetes Mellitus in Egyptian Children
Mosaad, Y. M., Elsharkawy, A. A., & Eldeek, B. S. (2011) · Immunological Investigations · doi:10.3109/08820139.2011.579215 · Cited by 37
The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis
Li, G., Shi, F., Liu, J., & Li, Y. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0157-0 · Cited by 37
CD28, CTLA-4 and CCL5 gene polymorphisms in patients with rheumatoid arthritis
Luterek-Puszyńska, K., Malinowski, D., Paradowska‐Gorycka, A., Safranow, K., & Pawlik, A. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3496-2 · Cited by 37
Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants
de Jong, V. M., Zaldumbide, A., van der Slik, A. R., Persengiev, S. P., Roep, B. O., & Koeleman, B. P. C. (2012) · Genes and Immunity · doi:10.1038/gene.2012.38 · Cited by 36
Torres‐Carrillo, N., Ontiveros-Mercado, H., Torres-Carrillo, N. M., Parra‐Rojas, I., Rangel‐Villalobos, H., Ramírez‐Dueñas, M. G., Gutiérrez-Ureña, S. R., Valle, Y., & Muñóz-Valle, J. F. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9640-6 · Cited by 36
Lee, Y. H., Choi, S. J., Ji, J. D., & Song, G. G. (2002) · Scandinavian Journal of Rheumatology · doi:10.1080/030097402760375142 · Cited by 36
Genomic regulation of CTLA4 and Multiple Sclerosis
Palacios, R., Comas, D., Elorza, J., & Villoslada, P. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.021 · Cited by 34
Watanabe, K., Rao, V. P., Poutahidis, T., Rickman, B. H., Ohtani, M., Xu, S., Rogers, A. B., Ge, Z., Horwitz, B. H., Fujioka, T., et al. (2008) · Infection and Immunity · doi:10.1128/iai.00542-08 · Cited by 34
Expression of CTLA‐4 and FOXP3 in cis protects from lethal lymphoproliferative disease
Chikuma, S., & Bluestone, J. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737159 · Cited by 33
Liu, C.-P., Jiang, J.-A., Wang, T., Liu, X.-M., Gao, L., Zhu, R., Shen, Y., Wu, M., Xu, T., & Zhang, X. (2013) · Genetics and Molecular Research · doi:10.4238/2013.april.25.8 · Cited by 33
Genovese, M. C., Pacheco‐Tena, C., Covarrubias, A., León, G., Mysler, E., Keiserman, M. W., Valente, R., Nash, P. T., Campos, J. A. S., Box, J., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130112 · Cited by 33
Wagner, M., Sobczyński, M., Karabon, L., Bilińska, M. M., Pokryszko‐Dragan, A., Pawlak, E., Cyrul, M., Kuśnierczyk, P., & Jasek, M. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.09.004 · Cited by 32
Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes
Haseda, F., Imagawa, A., Murase‐Mishiba, Y., Sano, H., Hirano-Kuwata, S., Ueda, H., Terasaki, J., & Hanafusa, T. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.05.003 · Cited by 31
Novel therapeutic targets in the treatment of IBD
Kaser, A., & Tilg, H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.553 · Cited by 30
CTLA-4 Negative Signaling via Lipid Rafts: A New Perspective
Rudd, C. E., Martı́n, M., & Schneider, H. (2002) · Science s STKE · doi:10.1126/stke.2002.128.pe18 · Cited by 30
Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: A meta-analysis
Zhang, M., Ni, J., Xu, W., Wen, P., Qiu, L., Wang, X., Pan, H., & Ye, D. (2014) · Human Immunology · doi:10.1016/j.humimm.2013.12.008 · Cited by 30
Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis
Langdon, K., & Haleagrahara, N. (2018) · International Reviews of Immunology · doi:10.1080/08830185.2018.1465943 · Cited by 30
Pérez-García, A., Osca‐Gelis, G., Bosch-Vizcaya, A., Kelleher, N., Santos, N., Rodríguez-Romanos, R., González, Y., Roncero, J. M., Coll, R., Serrando, M., et al. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.05.012 · Cited by 29
Ctla4 and multiple sclerosis in the Italian population
Malferrari, G., Stella, A., Monferini, E., Saltini, G., Proverbio, M. C., Grimaldi, L. M. E., Rossi-Bernardi, L., & Biunno, I. (2004) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2004.10.001 · Cited by 28
Zhang, M. S., Tran, P. M., Wolff, A. J., Tremblay, M. M., Fosdick, M. G., & Houtman, J. C. D. (2018) · Science Signaling · doi:10.1126/scisignal.aam9095 · Cited by 28
Ulzheimer, J. C., Meuth, S. G., Bittner, S., Kleinschnitz, C., Kieseier, B. C., & Wiendl, H. (2010) · BioDrugs · doi:10.2165/11537160-000000000-00000 · Cited by 27
Bagos, P. G., Karnaouri, A., Nikolopoulos, G. K., & Hamodrakas, S. J. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507078059 · Cited by 27
Overexpression of the CTLA-4 Isoform Lacking Exons 2 and 3 Causes Autoimmunity
Liu, S. M., Sutherland, A. P. R., Zhang, Z., Rainbow, D. B., Quintana, F. J., Paterson, A. M., Sharpe, A. H., Oukka, M., Wicker, L. S., & Kuchroo, V. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102042 · Cited by 27
CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese
Fukazawa, T., Kikuchi, S., Miyagishi, R., Niino, M., Yabe, I., Hamada, T., & Sasaki, H. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.10.012 · Cited by 26
Hayashi, H., Kusaka, I., Nagasaka, S., Kawakami, A., Rokkaku, K., Nakamura, T., Saito, T., Higashiyama, M., Honda, K., Ishikawa, S., et al. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00890.x · Cited by 24
No evidence of a significant role for CTLA-4 in multiple sclerosis
Roxburgh, R. H., Sawcer, S. J., Maranian, M. J., Seaman, S. R., Hensiek, A. E., Yeo, T. W., Deans, J., & Compston, A. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.006 · Cited by 24
Mayer, L., Kaser, A., & Blumberg, R. S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.015 · Cited by 24
Association of the CTLA-4 +49A/G polymorphism with rheumatoid arthritis in Chinese Han population
Tang, M., & Zhou, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2349-6 · Cited by 24
Tsukahara, S., Iwamoto, T., Ikari, K., Inoue, E., Tomatsu, T., Hara, M., Yamanaka, H., Kamatani, N., & Momohara, S. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.079186 · Cited by 18
Oki, S., Kohsaka, T., & Azuma, M. (1999) · International Immunology · doi:10.1093/intimm/11.9.1563 · Cited by 17
CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
Lee, Y. H., Kim, J., Seo, Y. H., Choi, S. J., Ji, J. D., & Song, G. G. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.02.020 · Cited by 16
Abatacept for systemic lupus erythematosus: the outlook
Mok, C. C. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.721773 · Cited by 16
Jiang, T., Ge, L., Zhi Tao, C. H. E. N., Li, C., Zhou, F., Luo, Y., & Xia, B. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00462.x · Cited by 11
Distinct NF-kB activation pathways engaged by T-cell receptor and co-receptor CD28 on T-cells
Thaker, Y. R., & Rudd, C. E. (2015) · Inflammation and Cell Signaling · doi:10.14800/ics.613 · Cited by 8
Activation of PXR inhibits LPS-induced NF-κB activation by increasing IκBα expression in HepG2 cells
Ye, N., Wang, H., Li, Q., Lin, C., Feng, H., Lin, S., Hong, J., & Meng, C. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0012-6 · Cited by 8
Cited by
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C.-F., & Wu, T.-C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 395
Advances in immunotherapy for triple-negative breast cancer
Liu, Y., Hu, Y., Xue, J., Li, J., Yi, J., Bu, J., Zhang, Z., Qiu, P., & Gu, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01850-7 · Cited by 337
Metadata
- Authors
- Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 80
- Pages
- 106221
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W3003395886
- Cited by
- 297
- References
- 256
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.